REV1 and ovarian cancer: We found that high REV1 expression is associated with poorer prognosis in colorectal (DSS: HR, 3.15, 95% CI, 1.05–9.39, p = 0.039999; DFS: HR, 2.72, 95% CI, 1.04–7.16, p = 0.041971) and ovarian cancer (overall survival (OS) 1: HR, 1.72, 95% CI, 1.10–2.67, p = 0.016573; OS 2: HR, 1.50, 95% CI, 1.06–2.12, p = 0.022128) (Figures 8A–D).